CA-ANOMALI
1.8.2022 11:02:08 CEST | Business Wire | Press release
Anomali , a leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions, today announced that Steve Benton has been appointed to the position of Vice President of Anomali Threat Research (ATR) and General Manager of the Anomali Belfast, Ireland Office. Benton, an experienced cyber security expert has a history of strategic advisory, intelligence sharing and coordinated response across MD, CxO, and board audiences. Benton joins Anomali during a time of rapid global expansion, to deliver guidance to global organizations on investment, strategy and making security a business enabler to rapidly address the evolving global threats of today and in the future.
“Steve brings a wealth of experience to Anomali – both in cybersecurity and in building and contributing to the wider security community. His experience and expertise spanning cyber security advisory, thought leadership, strategic development and execution will be a tremendous asset to our customers, partners, and investors,” said Mark Alba, CPO. “Steve’s extensive experience and expertise has been instrumental in helping guide global organizations on what is required to operate successfully in an ever-increasing and complex threat environment. We are very excited about Steve playing a pivotal role in how Anomali solutions can further help customers to thrive, grow and face security challenges with confidence.”
Benton has more than three decades of experience working with customers to solve their most difficult security challenges. Most recently, Benton was Deputy CISO and latterly CSO for BT where he was accountable for physical and cyber security across investment, posture, and response globally. While at BT, he built and led the Protect BT Services and Operations organization spanning intelligence, offensive security, cyber security operations, physical security operations, strategy, investigations, and incidents. In addition, he innovated proactive threat hunting and wide-ranging intelligence operations to anticipate threats, track threat actors, and their methods. An industry security expert, Benton is a contributing member of the Cyber Defenders Council, Fellow of the Chartered Institute of Information Security and a regular speaker and influencer to the i4 C level community.
“I am excited to join Anomali, the leader of threat-intelligence driven solutions, and contribute to the mission of helping organizations efficiently and effectively stop breaches and advanced adversaries,” said Benton. “As a previous customer, I leveraged the Anomali portfolio at the heart of my drive to improve security posture and disrupt threat actor activities at pace, whilst driving the democratisation of threat intelligence across the business. To know yourself and your adversaries through high fidelity, actionable intelligence, that constantly informs your decisions and guides a dynamic security posture, is the new battleground. And I look forward to bringing my frontline operational and strategic experience to Anomali customers and partners. With cyberattacks on the rise, ever more complex and multidimensional, organizations require an integrated XDR solution to tell them who they are up against, why, when they are being attacked, and how to accelerate their multifaceted response. The Anomali Platform greatly enhances an organization’s ability to address newly detected attacks, cresting threats and subsequent future attacks. Put simply, confidence in the face of uncertainty.”
For more information, visit:
www.anomali.com
Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog
About Anomali
Anomali is the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions. Anchored by big data management (the “X”) and refined by artificial intelligence, The Anomali Platform, an XDR solution, delivers unique proprietary capabilities that correlate the largest repository of global intelligence with telemetry from customer-deployed security solutions. This combination empowers security operations teams to detect threats with precision, optimize response, achieve resiliency, and ultimately stop attackers and breaches. Our SaaS-based solutions easily integrate into existing security tech stacks through native-cloud, multi-cloud, on-premises, and hybrid deployments. Founded in 2013, Anomali serves global B2B enterprise businesses and large public sector organizations, ISACs, ISAOs, service providers, and Global 1000 customers to help safeguard the world’s critical infrastructure, businesses, and people. Leading venture firms, including Google Ventures, General Catalyst, and IVP, back Anomali.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220729005511/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
